Navigation Links
ViewPoint CK System (Conductive Keratoplasty)

ProductsViewPoint CK System (Conductive Keratoplasty)
Company Refractec, Inc.
Item ViewPoint CK System (Conductive Keratoplasty)
Features Presbyopic Indications
Approval of the premarket approval application supplement for the Refractec ViewPoint CK System is for the temporary induction of myopia (-1.00 D to -2.00 D) to improve near vision in the non-dominant eye of presbyopic hyperopes or presbyopic emmetropes, via spherical hyperopic treatment of 1.00 D to 2.25 D, in patients 40 years of age or greater with a documented stability of refraction for the prior 12 months, as demonstrated by a change of < 0.50 D in spherical and cylindrical components of the manifest refraction, and with = 0.75 D of cycloplegic refractive cylinder and with a successful preoperative trial of monovision or history of monovision wear (i.e., dominant eye corrected for distance vision and non-dominant eye corrected for near vision).

Hyperopic Indications
The Refractec ViewPoint CK System is for the temporary reduction of spherical hyperopia in patients who have 0.75 D to 3.25 D of cycloplegic spherical hyperopia, less than or equal to 0.75 D of refractive astigmatism (minus cylinder format), and a cycloplegic spherical equivalent of +0.75 D to +3.00 D. Patients must be 40 years of age or greater with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than 0.50 D in spherical and cylindrical components of manifest refraction. The magnitude of correction with this treatment diminishes over time, with some patients retaining some or all of their intended refractive correction.

Description NearVision™ CK is the only procedure designed for patients with a spherical hyperopia between +0.75 D and +3.00 D or presbyopic patients who would benefit from a spherical treatment of between 1.00 D and 2.25 D to achieve a myopic endpoint of between -1.00 D and -2.00 D in their non-dominant eye to temporarily improve near vision. CK is unique in that it uses radiofrequency (RF) instead of a laser. It takes as little as three minutes and can be conveniently performed in-office using the ViewPoint CK System.

NearVision CK builds upon the principles of thermokeratoplasty, using radiofrequency (RF) energy to temporarily reshape the cornea and therefore adjust its refractive characteristics.

RF energy and its application
To perform the procedure, a handpiece with a Keratoplast™ Tip delivers controlled RF energy directly to the internal corneal tissue in a ring pattern. The tip serves as an RF antenna while the speculum holding the eye open serves as the return path. By applying RF energy to the tissue, Ohm's law (V = I R) defines a consistent relationship that determines the heat generated. The voltage (V) determines the electrical field strength within the tissue while the current (I) is defined by the treatment parameters. Impedance is a characteristic of tissue.

The characteristics of the energy (i.e., current, waveform, frequency, rep rate and crest factor) and the tissue's consistent conductive properties make it possible for CK to achieve a reproducible, optimal tissue temperature for the critical time necessary to bring about the localized shrinkage of the collagen fibers.

Depth of procedure and effects
CK creates a purse-string effect that steepens the central cornea through a ring of application spots around the periphery of the cornea. Several studies have concluded that the depth of shrinkage determines the degree of corneal correction permanency. Because of the intrastromal delivery of RF energy, CK produces collagen shrinkage that encompasses 80% of the corneal thickness.

Info Refractec, Inc.
Customer Service: (800) 752-9544
Web site: http://www.refractec.com

Related medicine products :

1. Silicone Oil Cannula System - 20 Gauge
2. Silicone Oil Cannula System - 19 Gauge
3. SuperVu Galilean System
4. KOWA nonmyd 7 / VK-2 Digital Imaging System
5. KOWA nonmyd a-D / VK-2 Digital Imaging System
6. Refraction System RT-2100
7. Odyssey Phacoemulsification System
8. SIStem Phacoemulsification System
9. Precisionist Phacoemulsification System
10. Photon Laser Phacoemulsification System
11. Phaco-Emulsification System
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products:
(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...
(Date:12/5/2009)... CAPE TOWN, South Africa, December 5 The ... outskirts of Cape Town opened its doors,today (5 ... joined by,Western Cape Premier Helen Zille, 2010 FIFA ... Jordaan, South African Football Association,President Kirsten Nematandani and ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
(Date:12/5/2009)... myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the ... tying the knot, since research has shown that never-married adults ... there something wrong with those who go it alone anyway? ... psychological measures shows that never-married people aged 40 and up ...
(Date:12/5/2009)... new international private medical insurance plan which follows the acclaimed modular ... flexibility to add or remove a wide range of options to ... their benefits to complement those already offered in their country of ... ...
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2
... March 19 NHS Choices ( http://www.nhs.uk ), ... new Good Food package aimed to,help people achieve ... improved,knowledge of the nutritional content of the food ... the Live Well package,( http://www.nhs.uk/Livewell/loseweight/Pages/Goodfoodhomehome.aspx ) enables,users to ...
... 19 Digirad Corporation,(Nasdaq: DRAD ), ... products,and services to physicians, offices, hospitals and ... has appointed veteran healthcare executive,John W. Sayward ... Mr. Sayward, 56, has more than 30 ...
... the HIV/AIDS epidemic increases food insecurity in African cities ... chances of this happening is the focus of a ... and Southern African expertise will be used in developing ... crucial issue. , Funded by the Canadian International Development ...
... of California,s Quality-in-Sights ... Hospital Incentive Program, THOUSAND ... Cross) today announced the introduction of its,Quality-in-Sights Hospital Incentive Program ... financial incentives with quality,improvements. It uses select indicators that have ...
... to drug-resistant bacteria, CDC study finds , , WEDNESDAY, March ... Staphylococcus aureas bacterium and caught outside of the ... States than previously believed, preliminary research suggests. , "Over ... of a severe CAP [community-acquired pneumonia] caused by ...
... Texas, Struggling Medicaid,Program, AUSTIN, Texas, March 19 ... proposed budget and regulatory,changes that will cut Medicare-financed nursing ... ahead - the 4th highest level of cuts in ... per day - national,and state long term care leaders ...
Other Medicine News:Health News:Digirad Corporation Appoints John W. Sayward to Its Board of Directors 2Health News:Digirad Corporation Appoints John W. Sayward to Its Board of Directors 3Health News:Digirad Corporation Appoints John W. Sayward to Its Board of Directors 4Health News:Food insecurity linked with HIV/AIDS in Africa 2Health News:Blue Cross of California Introduces Pay-for-Performance Hospital Program 2Health News:Community-Based Staph Pneumonia More Common Than Thought 2Health News:New Analysis of Bush FY 2009 Budget: Texas Medicare Cuts 4th Highest in Nation 2Health News:New Analysis of Bush FY 2009 Budget: Texas Medicare Cuts 4th Highest in Nation 3
(Date:12/4/2009)... of imported drugs often stored in tin cans and car ... senior advocacy group RetireSafe urged the Senate to defeat the ... Phillips said, "Senator Dorgan,s importation amendment is poised to open ... breached, and our health to be endangered. We could ...
(Date:12/4/2009)... N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed ... Food and Drug Administration seeking approval to market its ... patent owned by Takeda Pharmaceutical Company Limited. Watson,s ...
(Date:12/4/2009)... RARITAN, N.J., Dec. 4 Depression, anxiety disorder, ... disorder and migraine: These are among the comorbidities ... said they had been diagnosed with epilepsy versus ... survey of approximately 173,000 households across the U.S. ...
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 1Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 2Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 3Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 4Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 5Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting 54852 6COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 54849 1COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 54849 2Los Gatos Research Introduces Second Generation Liquid Water Isotope Analyzer 13628 1Los Gatos Research Introduces Second Generation Liquid Water Isotope Analyzer 13628 2